Eli Lilly will raise the list price in the UK of its weight-loss and type 2 diabetes treatment Mounjaro by 170% to be in line with other European markets, the U.S. drugmaker said on Thursday. Lilly launched Mounjaro in the UK in February last year,

Eli Lilly will increase the UK price of its Mounjaro treatment by 170% to match European markets. Despite Novo Nordisk's initial market lead with Wegovy, Mounjaro's sales have surged. The NHS will maintain access to the drug despite the price hike,

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials. The weight loss pill also significantly improved heart health markers like cholesterol and blood pressure.